We serve Chemical Name:7-(Trifluoromethyl)indoline-2,3-dione CAS:391-12-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:7-(Trifluoromethyl)indoline-2,3-dione
CAS.NO:391-12-8
Synonyms:MFCD01248408;7-(Trifluoromethyl)indole-2,3-dione;7-(TrifluoroMethyl)isatin;7-(Trifluoromethyl)-2,3-indolinedione;7-(Trifluoromethyl)indoline-2,3-dione;1H-Indole-2,3-dione, 7-(trifluoromethyl)-;7-trifluoromethylisatin;7-(Trifluoromethyl)-1H-indole-2,3-dione
Molecular Formula:C9H4F3NO2
Molecular Weight:215.129
HS Code:2933990090
Physical and Chemical Properties:
Melting point:192-193
Boiling point:N/A
Density:1.5±0.1 g/cm3
Index of Refraction:1.513
PSA:46.17000
Exact Mass:215.019409
LogP:1.75
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like MFCD01248408 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7-(Trifluoromethyl)-1H-indole-2,3-dione physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-(Trifluoromethyl)indole-2,3-dione Use and application,7-(Trifluoromethyl)indoline-2,3-dione technical grade,usp/ep/jp grade.
Related News: It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time. 1,5-dichloroheptafluoro-3-aza-2-pentene manufacturers “This is the beginning of the next chapter of growth for BetterUp, and we are not slowing down,” said Alexi Robichaux, CEO and co-founder of BetterUp. “Though we have done business in Europe since 2016, we are committing to a new level of investment in our customers, coaches, and communities by establishing offices in Munich and London. 2-(sym-dibenzo-16-crown-5-oxy)hexanoic acid suppliers Patients having Zynteglo treatment for beta thalassaemia also need conditioning treatment to clear out their bone marrow cells before receiving Zynteglo. Healthcare professionals should therefore explicitly inform patients receiving Zynteglo of the increased risk of blood cancers from medicines used in conditioning treatments. 6-(5-acetyl-7-methylcoumarinyl)oxyacetic acid vendor & factory.
